Free tool
FAERS Monitor: Vegzelma
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761268 or its brand name (Vegzelma, Bevacizumab-Adcd). Reports on generic versions are filed under their own applications.
Reports
203
Serious
184
91% of reports
Hospitalization
74
Death reported
22
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- intentional product use issue28
- neutropenia27
- diarrhoea18
- neuropathy peripheral16
- pyrexia13
- asthenia12
- thrombocytopenia12
- nausea11
- drug ineffective9
- vomiting9
- decreased appetite8
- headache8
- therapy cessation8
- intentional dose omission7
- leukopenia7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 4 |
| 2024 | 21 |
| 2025 | 78 |
| 2026 | 100 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,956 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intentional product use issueSignal | 28 | 33.1 | 23.5 | 844 |
| intentional dose omissionSignal | 7 | 25.4 | 12.3 | 141 |
| neutropeniaSignal | 27 | 20.6 | 14.5 | 487 |
| neuropathy peripheralSignal | 16 | 17.4 | 10.9 | 233 |
| therapy cessationSignal | 8 | 16.1 | 8.2 | 99 |
| leukopeniaSignal | 7 | 14.5 | 7.0 | 75 |
| thrombocytopeniaSignal | 12 | 11.1 | 6.4 | 101 |
| pyrexiaSignal | 13 | 3.9 | 2.3 | 26 |
| decreased appetiteSignal | 8 | 3.6 | 1.8 | 12 |
| astheniaSignal | 12 | 3.3 | 1.9 | 17 |
| diarrhoeaSignal | 18 | 2.9 | 1.9 | 21 |
| vomiting | 9 | 2.0 | 1.0 | 4 |
| nausea | 11 | 1.4 | 0.8 | 1 |
| headache | 8 | 1.3 | 0.7 | 0 |
| drug ineffective | 9 | 0.7 | 0.4 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.